Cas:34446-64-5 (2E)-3-(4-Methoxyphenyl)acryloyl chloride manufacturer & supplier

Chemical Name:(2E)-3-(4-Methoxyphenyl)acryloyl chloride

CAS.NO:34446-64-5

Synonyms:p-Methoxycinnamic acid chloride;4-Methoxycinnamic acid chloride;p-Methoxycinnnamoyl chloride;2-Propenoyl chloride, 3-(4-methoxyphenyl)-, (2E)-;P-Methoxyl ethyl CinnaMyl;p-Methoxycinnamoyl chloride;para-methoxycinnamic acid chloride;(2E)-3-(4-methoxyphenyl)prop-2-enoyl chloride;(2E)-3-(4-Methoxyphenyl)acryloyl chloride;trans-4-Methoxycinnamoyl chloride

Molecular Formula:C₁₀H₉ClO₂

Molecular Weight:196.630

HS Code:

Physical and Chemical Properties:

Melting point:49-50ºC

Boiling point:317.2±17.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.573

PSA:26.30000

Exact Mass:196.029114

LogP:3.13

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN3261 8/PG 2

Packing Group:

Contact us for information like p-Methoxycinnamic acid chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,trans-4-Methoxycinnamoyl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,p-Methoxycinnamic acid chloride Use and application,(2E)-3-(4-Methoxyphenyl)acryloyl chloride technical grade,usp/ep/jp grade.

Related News: The market for pharmaceutical intermediates is vast and is expected to usher in new growth. Compared with the pesticide intermediate business, the market space for pharmaceutical intermediates is larger and will be the focus of the company’s future development. (2E)-3-(4-Methoxyphenyl)acryloyl chloride manufacturer The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. (2E)-3-(4-Methoxyphenyl)acryloyl chloride supplier The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. (2E)-3-(4-Methoxyphenyl)acryloyl chloride vendor The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. (2E)-3-(4-Methoxyphenyl)acryloyl chloride factory Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries.